Navigation Links
Limiting Eligibility for Medical Studies Can Omit Women,,African-Americans, Stanford Study Finds

his reason, the National Institutes of Health has instructed researchers to design their studies to ensure adequate enrollment of all populations, including women and racial minorities.

"The NIH, and we as a society, have decided that the burden and benefits of health research should be shared by everyone," said Humphreys, who is also on the staff of the Veterans Affairs Palo Alto Health Care System. "It's a moral and political stance and we're obligated to live up to it."

For the analysis, Humphreys and his colleagues looked at data sets from five previous alcohol treatment studies that enrolled more than 100,000 patients. They then explored the impact of six exclusion criteria commonly used in treatment outcome research: psychiatric problems, neurological problems, medical problems, drug use, non-compliance issues, and social and residential instability.

The researchers found that women were 62 percent more likely than men to be disqualified from studies that required social and residential stability. Women were 29 percent more likely to be excluded from studies that disqualified patients with psychiatric problems, and 20 percent more likely to be excluded for medical problems.

They also found that African-Americans were 46 percent more likely than non-African-Americans to be excluded from studies that required social and residential stability, and 23 percent more likely to be excluded based on drug-use criteria.

"The end result can be a sample that over-represents Caucasian males relative to the treatment population," the authors noted in their paper.

Humphreys stressed that he doesn't believe his fellow researchers are acting out of prejudice or purposefully excluding patients. "Most researchers want women in the studies, but they don't realize that the way they design the study undermines their intentions," he said. "A researcher may say, 'I don't want anyone who is depressed in my alcohol study,' and not stop to consid
'"/>




Page: 1 2 3

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
10. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
11. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
Post Your Comments:
(Date:7/23/2008)...Company Focused on IND-Enabling Work with Protein ...athway of Complement System, CAMBRIDGE, Mass., Ju...day announced it has initiated a corporate growth ..., as chief executive officer and the,establishment...ker succeeds,Woodruff Emlen, M.D., a co-founder of...
(Date:7/22/2008)...- Strong efficacy results from a multi-center 293-...com , Toronto Stock Exchange Symbol: CYT, MONTRE...echnologies,Inc., the global leader in cryotherapy...unced that results previously presented from three...roduct, Arctic Front(R),were published earlier to...
(Date:7/22/2008)...Latest awards under Therapeutics Development Initi...rations to 23; next deadline January 20,2009, NE... of its mission to,speed delivery of transformativ...he Michael J. Fox Foundation for Parkinson,s Resea...ix industry research teams. The awards,were grante...
(Date:7/22/2008)...tudy Demonstrates Feasibility and Efficacy of Trea...y Liver Cancer, SAN FRANCISCO, and YONGIN-SI, Sou...San Francisco, CA and Ottawa, Ontario), and its So...day that novel findings from,a Phase I clinical tr...nstrated that the product was well-tolerated and r...
Breaking Medicine Technology:Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Psoriasis Study Showing Increased Risk of Death Underscores Need for More Research Group Says 8476 1MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 1MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 2MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 3Synthetech Earns National Recognition for Performance Improvement Program 2270 1Synthetech Earns National Recognition for Performance Improvement Program 2270 2Synthetech Earns National Recognition for Performance Improvement Program 2270 3Researchers hope to provide chronic fatigue syndrome answers 8470 1Researchers hope to provide chronic fatigue syndrome answers 8470 2
...History Highlighted in AACR Cancer Journal , AUSTI...Therapeutics, Inc. (NASDAQ:INGN) announced today t...nical benefit of its lead product,Advexin in a pat...,Li-Fraumeni Syndrome (LFS), a genetic disorder ch...r suppressor gene. This is the,first reported trea...
...LLE, Md.--(BUSINESS WIRE)--May 30, 2007 - Rexahn,P...tical company,dedicated to the discovery, developm...s for cancer, central nervous system disorders,se...day announced,that Dr. John Marshall, Principal In...y,s lead cancer compound RX-0201 (Archexin),will ...
Other Medicine Technology:Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 2Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 3Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 4
(Date:7/25/2008)...CESS, N.Y., July 25 /PRNewswire-USNewswire/ -- Ant...f Quality Officer and Vice President,of Strategic ...th Fund, a,national foundation committed to improv...ted the foundation,s Program on Health Care Qualit....newscom.com/cgi-bin/prnh/20080725/DC28791LOGO ),...
(Date:7/25/2008)...ON, Calif., July 25 /PRNewswire-FirstCall/ -- Thor...n device-based mechanical,circulatory support ther...,today announced that it will report its operating...hs of fiscal 2008 on Thursday, July 31., The comp...ancial,results and operating activities to all int...
(Date:7/25/2008)...A July 24, 2008 Being overweight or obese is not...ut is also a public health issue that impacts othe...ealth Services Research reveals that the extra Me...ple could place a significant financial burden on ...dollars across the entire current Medicare populat...
(Date:7/25/2008)...July 25 /PRNewswire/ -- BeaconEquity.com announces... news today., Investors can view all of the daily...nEquity.com/m , Today,s Trade Alerts include: DUS...ok Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaMed ..., Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis Inc....
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3
... Industries Ltd today said it has acquired a signi...ary of US-based indigene Pharma Inc// , for an und...iopharmaceuticals, has been in the business of bot... healthcare products. Commenting on the strategic...
...discovery may help treat stroke-affected humans Ne...s recover after a stroke by stimulating a protein/...pes about the possibility of repairing the human b...h as stroke or spinal-cord damages. The findings ...
...ciate Health Minister Jim Anderton said that the G... people in all age groups//. New Zealand has a ve...given to bring down youth suicide rates. According...ms in 2003 were aged 25 or older. Suicide rates am...
...archers have concluded that earlier a deaf child r...r spoken language skills, sentence formation and u...deaf but used cochlear implants, able to hear part...he right time to make use of it. In contrast, a c...
Other Medicine News:Health News:Earlier the Cochlear Implants Used Better the Speech 2Health News:Earlier the Cochlear Implants Used Better the Speech 3
Every so often a new product comes along that isn't a small step but a giant leap ahead of everything that has preceeded it. Such is the impact of the Fidelity IAB.
...the perfect partner for growing your business prac...e scalable to meet your needs now and in the years...r FD20 system supports mixed-use as well as dedica...ws you to add new applications and techniques such...
...on CFX series represents a breakthrough that makes...ty. Its revolutionary design integrates Quantum 64...ies and advanced software. In fact, Aquilion CFX ... shown a sensitivity of 88% and specificity of 91%...
...2000 represents a new non-invasive approach to the...stem rapidly induces mild hypothermia in those pat...ia or rapidly reduces temperature in febrile patie...aintains core body temperature in a range of 33C (...
Medicine Products: